SAN DIEGO, July 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today second quarter financial results for the period ended June 30, 2005.
The Company reported second quarter revenues of $15.0 million, a 70.7% increase over the $8.8 million for the second quarter of 2004 and a 15.1% increase over the $13.1 million for the first quarter of 2005. Maximum Access Surgery (MAS) revenues for the second quarter were $12.6 million, an increase of 103.5% from the second quarter of 2004, and an increase of 26.5% from the first quarter of 2005.
Gross profit for the second quarter of 2005 was $11.9 million with a gross margin of 78.9%, including a charge of $497,000 for the write-off of investments in fixed assets and inventory related to the initial alpha/beta testing of the Company's cervical plate under development. Excluding this charge, non-GAAP gross profit for the second quarter of 2005 was $12.4 million with a gross margin of 82.2%, compared with a gross profit of $6.3 million with a gross margin of 71.8% in the second quarter of 2004. For the first quarter of 2005, gross profit was $10.4 million with a gross margin of 79.9%. The continued strong gross margin for the second quarter of 2005 was due primarily to the product revenue mix of 83.5% MAS revenues and 16.5% classic fusion revenues and to the mix of products within MAS, specifically NeuroVision and MaXcess disposables, and specialized implants.
Total operating expenses for the second quarter of 2005 were $16.3 million, compared with $10.8 million in the second quarter of 2004 and $14.3 million in the first quarter of 2005. Total non-GAAP operating expenses, excluding stock-based compensation expense and the charges detailed in the next paragraph, for the second quarter of 2005 were $15.0 million, compared with $8.9 million in the second quarter of 2004 and $13.4 million for the first quarter of 2005. The quarter-over-quarter increase reflects continued investment in the Company's next generation MAS products, accelerated surgeon and sales representative training, and marketing and trade show related costs. Included in the quarter-over-quarter increase is additional sales and marketing expenses related to the Company's program to transition its distributor network toward exclusivity.
The Company recorded charges of $904,000 in the second quarter. A charge to cost of goods sold of $497,000 was recorded for investments in fixed assets and inventory for the initial alpha/beta testing of the Company's cervical plate that was under internal development. The cervical plate was replaced by the acquisition of intellectual property and related assets for cervical plate technology from RSB Spine LLC. The Company also recorded charges to general and administrative expenses totaling $407,000 during the second quarter, $237,000 of which was related to due diligence costs associated with an abandoned technology acquisition, and $170,000 for certain legal expenses.
On a GAAP basis for the three-month period ended June 30, 2005, the Company reported a net loss of $4.1 million, or $0.17 per share. On a non-GAAP basis, second quarter net loss, excluding the above acquisition-related charges and stock based compensation, was $2.3 million, or $0.10 per share.
Cash, cash equivalents and short-term investments were $40.8 million at June 30, 2005.
Alexis V. Lukianov, Chairman and Chief Executive Officer, said, "Our strong second quarter results reflect the considerable progress we continue to make in penetrating the spine surgeon marketplace with our MAS platform. During the quarter, we trained a total of 119 surgeons in our cadaver operating facility and remain well on track to achieve our stated goal of over 425 surgeons trained for the year. We are particularly pleased with the advancements we have made to acquire and introduce new technology. Our acquisition of an advanced dynamic cervical plate, re-launched as 'SmartPlate Gradient CLP', increases our product breadth bringing greater opportunity of increased distributor exclusivity. The recently launched SpheRx. DBR percutaneous pedicle screw system has received positive feedback from surgeons since its launch in the second quarter. Most recently, we filed an IDE with the FDA for Cerpass(TM), our cervical total disc replacement product. The quarterly developments involved one-time charges and increased expenses that we view as investments in our long-term goal of becoming the leading, independent company focused solely on minimally disruptive surgical treatments of the spine."
For the full year 2005, the Company increased revenue guidance to be in the range of $61 million to $62 million, from its previous guidance range of $59 million to $61 million.
Management uses certain non-GAAP financial measures, such as non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net loss and non-GAAP net loss per share, which exclude the following charges: (i) stock based compensation, (ii) the write-off of investments in fixed assets and inventory related to the initial alpha/beta testing of the Company's cervical plate under development and (iii) certain other amounts which management has determined should not be considered in evaluating the continuing operations of the Company. Therefore, management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non- GAAP financial measures to enable it to analyze further and more consistently the period-to-period financial performance of its core business operations. Management believes that although it is important for investors to understand GAAP measures, providing investors with these non-GAAP measures gives them additional important information to enable them to assess, in a way management assesses, the Company's current and future continuing operations. These non- GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies.
NuVasive will hold a conference call at 5:30 p.m. EDT / 2:30 p.m. PDT to discuss the results. The dial-in numbers are (877) 407-4018 for domestic callers, and (201) 689-8471 for international. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate Web site at www.nuvasive.com.
After the live Web cast, the call will remain available on NuVasive's Web site, www.nuvasive.com, through August 26, 2005. In addition, a telephonic replay of the call will be available until August 18, 2005. The replay dial- in numbers are (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. Please use account number 3055 and conference ID number 161335.
NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(TM), as well as classic fusion implants.
The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings-NeuroVision(R), a proprietary software-driven nerve avoidance system; MaXcess(R), a unique split-blade design retraction system; and specialized implants, like SpheRx(TM) and CoRoent(TM)-that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's classic fusion portfolio is comprised predominantly of proprietary saline packaged bone allografts and internal fixation products. NuVasive also has a robust R&D pipeline emphasizing both MAS and motion preservation products such as Total Disc Replacement (TDR).
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to, the risk that our revenue projections may turn out to be incorrect because of unanticipated difficulty in selling our products; the uncertain process of seeking regulatory approval or clearance for NuVasive's products, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of our products to patients and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Contact: Investors: Kevin C. O'Boyle Stephanie Carrington/Nick Laudico EVP & Chief Financial Officer The Ruth Group NuVasive, Inc. 646-536-7017/7030 858-909-1800 firstname.lastname@example.org email@example.com firstname.lastname@example.org NUVASIVE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) Three Months Ended Three Months Ended June 30, 2005 June 30, 2004 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Basis Basis Basis Basis Revenues: MAS $12,557 $12,557 $6,171 $6,171 Classic Fusion 2,479 2,479 2,638 2,638 Total revenues 15,036 - 15,036 8,809 - 8,809 Cost of goods sold 3,178 (497) B 2,681 2,481 2,481 Gross profit 11,858 497 12,355 6,328 - 6,328 Operating expenses: Research and development 2,454 2,454 1,616 1,616 Sales and marketing 8,965 8,965 4,853 4,853 General and administrative 3,989 (407) C 3,582 2,469 2,469 Stock-based compensation 905 (905) A - 1,845 (1,845)A - Total operating expenses 16,313 (1,312) 15,001 10,783 (1,845) 8,938 Interest income (expense), net 345 345 (11) (11) Other expense, net - - - - Net loss $(4,110) $1,809 $(2,301) $(4,466) $1,845 $(2,621) Historical net loss per share: Basic and diluted $(0.17) $(0.10) $(0.34) $(0.20) Weighted average shares- basic and diluted 24,090 24,090 13,188 13,188 A - Stock-based compensation B - Write-off of investments in fixed assets and inventory related to the initial alpha/beta testing of the Company's own cervical plate under development. These were written-off as a result of the RSB Spine acquisition. C - Due diligence costs associated with an abandoned technology acquisition and legal costs related to specific and unusual matters that are not expected to be ongoing and that management has determined should not be considered in evaluating the continuing operations of the Company NUVASIVE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) Six Months Ended Six Months Ended June 30, 2005 June 30, 2004 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Basis Basis Basis Basis Revenues: MAS $22,480 $22,480 $10,974 $10,974 Classic Fusion 5,620 5,620 5,423 5,423 Total revenues 28,100 - 28,100 16,397 - 16,397 Cost of goods sold 5,805 (497) B 5,308 4,685 4,685 Gross profit 22,295 497 22,792 11,712 - 11,712 Operating expenses: Research and development 4,611 4,611 3,178 3,178 Sales and marketing 16,450 16,450 8,604 8,604 General and administrative 7,740 (407)C 7,333 4,554 4,554 Stock-based compensation 1,844 (1,844)A - 3,978 (3,978)A - Total operating expenses 30,645 (2,251) 28,394 20,314 (3,978) 16,336 Interest income (expense), net 685 685 (79) (79) Other expense, net - - (11) (11) Net loss $(7,665) $2,748 $(4,917) $(8,692) $3,978 $(4,714) Historical net loss per share: Basic and diluted $(0.32) $(0.20) $(1.17) $(0.64) Weighted average shares- basic and diluted 24,006 24,006 7,418 7,418 A - Stock-based compensation B - Write-off of investments in fixed assets and inventory related to the initial alpha/beta testing of the Company's own cervical plate under development. These were written-off as a result of the RSB Spine acquisition. C - Due diligence costs associated with an abandoned technology acquisition and legal costs related to specific and unusual matters that are not expected to be ongoing and that management has determined should not be considered in evaluating the continuing operations of the Company NUVASIVE, INC. CONSOLIDATED BALANCE SHEETS (in thousands) June 30, December 31, 2005 2004 Assets Current assets: Cash and cash equivalents $5,173 $8,560 Short-term investments 35,607 50,593 Accounts receivable, net 9,070 6,770 Inventory, net 9,311 5,249 Prepaid expenses and other current assets 1,333 826 Total current assets 60,494 71,998 Property and equipment, net 14,631 8,725 Intnagible assets, net 8,160 - Other assets 40 29 Total Assets $83,325 $80,752 Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued liabilities $8,231 $6,202 Accrued payroll and related expenses 3,630 3,135 Current portion of obligations under capital leases - 5 Total current liabilities 11,861 9,342 Obligations under capital leases, less current portion - 13 Other long-term liabilities 1,694 - Stockholders equity: Common stock 24 24 Additional paid-in capital 158,122 153,323 Deferred compensation (2,203) (3,441) Accumulated other comprehensive loss (42) (43) Accumulated deficit (86,131) (78,466) Total stockholders' equity 69,770 71,397 Total liabilities and stockholders' equity $83,325 $80,752 NUVASIVE, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Q105 Q205 YTD Net loss $(3,555) $(4,110) $(7,665) Add back Non-Cash Expenses - Depreciation and amortization 681 874 1,555 Write-off of cervical plate inventory - 497 497 Stock-based compensation 939 905 1,844 Other non-cash adjustments 198 (64) 134 Changes in operating assets and liabilities: - Accounts receivable (1,251) (1,050) (2,301) Inventory (971) (2,815) (3,786) Other current and long term assets (9) (509) (518) Accounts payable and accrued liabilities 2,215 (776) 1,439 Accrued payroll and related expenses (670) 1,140 470 Net cash used in operating activities (2,423) (5,908) (8,331) Investing activities: Cash paid for business combinations - (3,800) (3,800) Purchases of property and equipment (4,252) (2,679) (6,931) (Purchases) Sales of short-term investments, net 14,389 597 14,986 Net cash provided by (used in) investing activities 10,137 (5,882) 4,255 Financing activities: Payment of capital leases (1) (17) (18) Issuance of common stock 98 609 707 Net cash provided by financing activities 97 592 689 Increase (decrease) in cash and cash equivalents 7,811 (11,198) (3,387) Cash and cash equivalents at beginning of period 8,560 16,371 8,560 Cash and cash equivalents at end of period $16,371 $5,173 $5,173
SOURCE NuVasive, Inc.
Kevin C. O'Boyle, EVP & Chief Financial Officer of NuVasive, Inc., +1-858-909-1800, email@example.com; Investors - Stephanie Carrington, +1-646-536-7017, firstname.lastname@example.org, or Nick Laudico, +1-646-536-7030, email@example.com, both of The Ruth Group, for NuVasive, Inc.